Home Alzheimer’s Disease Timothy A. Yap, MBBS, PhD, FRCP, on COVID-19 Vaccination for Patients in...

Timothy A. Yap, MBBS, PhD, FRCP, on COVID-19 Vaccination for Patients in Phase 1 Cancer Trials

The medical oncologist and physician scientist based at the University of Texas MD Anderson Cancer Center explained recommendations for SARS-CoV-2 vaccination in patients participating in phase 1 oncology clinical trials.

In an article published in the Lancet Oncology, investigators propose guidelines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients participating in phase 1 oncology clinical trials.

Overall, the investigators indicated that even though there are risks in vaccinating this patient population, the potential benefit to patients should be judiciously balanced with the unknown effects. Thus, it is essential for providers to make decisions regarding vaccination on an individual basis with patients and their advocates.

“This is an opportunity for, and indeed a duty of, treating oncologists, trial sponsors, and regulatory agencies to…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments